Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1997-12-19
2000-05-30
Saunders, David
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
424810, 514 2, 514 12, 530350, A61K 3804, A61K 3817, C07K 100
Patent
active
060688440
ABSTRACT:
The present invention relates to a method of inducing oral tolerance to ischemic injury which has the objective of minimizing the severity and size of injured regions in the brain that arise as a result of ischemia. The method responds rapidly to the onset of infarction, with treatment that is short in duration. The procedure is specifically focused on the injured area of the infarct by virtue of being targeted immunologically to the ischemic site. The method therefore avoids the possibility of inducing systemic side effects affecting other organs of the patient. The present invention involves administering myelin or a component thereof such as myelin basic protein or proteolipid protein to a subject either orally or by inhalation. The amount administered and the duration of the treatment are effective to minimize the size and severity of the infarct in the brain of the subject. The method is intended for acute conditions related either to an actual recent cerebral ischemic event or to a potential ischemic event that might arise as a result of medical or surgical treatment planned for the subject.
REFERENCES:
patent: 5571500 (1996-11-01), Hafler et al.
patent: 5641474 (1997-06-01), Hafler et al.
patent: 5643868 (1997-07-01), Weiner et al.
patent: 5645820 (1997-07-01), Hafler et al.
patent: 5651993 (1997-07-01), Edelson et al.
Becker, KJ et al. Proc. Natl. Acad. Sci. (USA) vol. 94 pp. 10873-10878, Sep., 1997.
Kitamura, K et al. Biochim. Biophys. Acta. 379:582-591, 1975.
Tisch, R and McDevitt, HO. Proc. Nat. Acad. Sci. (USA) 91:437-438, Jan. 1994.
Brostoff, S. et al. Nature. 235:210-212, Feb. 1972.
Al-Sabbagh, A. et al. in: Autoimmune Disease Models: A Guidebook. Cohen and Miller, eds. Academic Press, San Diego, pp. 15-22, 1994.
Brocke, S. et al. in: Autoimmune Disease Models: A Guidebook. Cohen and Miller, eds. Academic Press, San Diego, pp. 1-14, 1994.
Gregorian, SK. et al. Cellular Immunology. 150:298-310, Sep. 1993.
Day, MJ. et al. J. Neuroimmunol. 34(2-3):197-203, Nov. 1991.
Weiner et al., "Double-Blind Pilot Trial of Oral Tolerization With Myelin Antigens in Multiple Sclerosis", Science, vol. 259. Feb. 26, 1993, pp. 1321-1324.
Weiner, "Oral Tolerance For The Treatment of Autoimmune Diseases", Annu. Rev. Med. 1997, 48:341-51.
Wang et al., "Myelin antigen reactive T cells in cerebrovascular diseases", Clin. exp. Immunol. (1992) 88, 157-162.
Hohol et al., "Three-year Open Protocol Continuation Study of Oral Tolerization With Myelin Antigens in Multiple Sclerosis and Design of a Phase III Pivotal Trial", Annals New York Acad. of Science, vol. 778, 1996, pp. 243-250.
Al-Sabbagh et al., "Decreased CNS Inflammation and Absence of Clinical Exacerbation of Disease After Six Months Oral Administration of Bovine Myelin in Diseases SJL/J Mice With Chronic Relapsing Experimental Autoimmune Encephalomyelitis", Journal of Neuroscience Research 45:424-429 (1996).
Mandai et al., "Ischemic Damage And Subsequent Proliferation of Oligodendrocytes in Focal Cerebral Ischemia", Neuroscience vol. 77, No. 3, pp. 849-861, 1997.
Kelly et al., "Oral tolerance in EAE: reversal of tolerance by T helper cell cytokines", Journal of Neuroimmunology 66 (1996) 77-84.
Becker Kyra J.
Hallenbeck John M.
McCarron Richard M.
Saunders David
The United States of America as represented by the Department of
VanderVegt F. Pierre
LandOfFree
Increased resistance to stroke by developing immunologic toleran does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Increased resistance to stroke by developing immunologic toleran, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Increased resistance to stroke by developing immunologic toleran will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1908168